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Figure 4. Cross-sectional view: potential design for the dual release of antibiotics and probiotics through the integration of 
a 2-compartmental porous system with hydrophobic and hydrophilic bioinks. 
Figure 3. (A) DuoCaplet design demonstrating rapid/delayed release of 2 drugs (acetaminophen and caffeine) loaded in PVA filaments4.          
(B) Polypill (5 drug) design composed of 1 immediate release compartment and 3 sustained-release compartments5. (C) Tablet design 
exploring various hole positions on release of anti-epileptic drugs6. (D) Intravaginal ring for controlled progesterone release7.
Figure 1. (A) Schematic representing vaginal flora in a BV state. (B) Examples of oral and 
vaginal dosage forms (C) Electrospun fiber fabricated in lab for vaginal delivery1. (D) Fiber at 
1,000X magnification1. 
Figure 2. (A) 3D bioprinter2 and (B) examples of 3D bioprinted shapes2. (C) 3D printed probiotic scaffold crosslinked with only CaCl2, compared 
with2 (D) scaffold crosslinked with both CaCl2 and genipin
3. 
• Bacterial Vaginosis (BV) is the most prevalent vaginal infection, 
affecting 30% of reproductive-age women in the United States 
and worldwide.
• BV is characterized by a shift in the vaginal microbiome from a 
dominance of Lactobacilli to the overgrowth of vaginal pathogens 
(specifically Gardnerella vaginalis).
• Some common complications include adverse pregnancy 
outcomes and increased risk for sexually transmitted diseases.
• Current treatment primarily involves antibiotics, but this is 
ineffective due to high antibiotic resistance and BV recurrence 
rates of 50%. Thus, a more permanent cure is sought.
• Lactobacilli probiotics are a promising alternative to antibiotics. 
They have shown success in reestablishing healthy flora, 
inhibiting pathogen growth, and reducing recurrence.
• Probiotics have been administered both orally and intravaginally, 
but vaginal delivery is preferred. 
• Unfortunately, present vaginal dosage forms require frequent 
administration, thereby decreasing user adherence and efficacy. 
• Only one sustained-release probiotic dosage form, in the form of 
pod-intravaginal rings, has been published to date. However this 
design leads to discomfort and is susceptible to biofilm formation.
• Therefore, an intravaginal probiotic delivery platform capable of 
sustained release and that offers women flexibility in dosage 
forms is necessary. 
• Objective: Our goal is to investigate unique 3D bioprinted architectures and identify design parameters 
that are important for sustaining the intravaginal release of probiotics over several days/weeks. 
• Methods: PubMed and Google Scholar were used to explore articles that demonstrated sustained 
release of active pharmaceutical agents through 3D printed platforms.
3D Bioprinting: Proof of Concept for Printing Probiotics
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• Encapsulation of probiotics within a hydrophilic matrix and subsequent coating of the 
scaffold with a hydrophobic polymer may sustain release and maintain structural 
integrity for longer time frames. (Fig. 3, B & D)
• Modification of material composition and architecture can yield dosage forms capable of 
releasing multiple active agents, each with customized release profiles. (Fig. 3, A & B)
– This suggests that immediate/rapid release of antibiotics followed by the sustained 
delivery of probiotics may be possible. 
• Present architectures focus on release of drugs much smaller than live cells. Diffusion 
through scaffold and ultimate release of probiotics will be more challenging due to their 
larger size.
– Porosity of scaffolds (as in Fig. 3, C) is therefore an important design parameter. 
• Present architectures demonstrate release on the order of few minutes to hours. Longer 
release times may be achieved by exploring other bioinks. 
• Future work will develop a SOLIDWORKS model; optimize printing parameters and 
print scaffolds; and assess release profiles, degradation and cell viability. 
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